{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:49:34Z","timestamp":1788608974006,"version":"build-2803163510"},"reference-count":35,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: To evaluate the effects of intravitreal ranibizumab on retinal nerve fiber layer (RNFL) thickness and optic disc parameters in patients treated for exudative age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Methods: This retrospective study analyzed the clinical records of 60 patients who received intravitreal ranibizumab injections for macular edema secondary to AMD, DME, or RVO between October 2014 and January 2016. All patients received intravitreal ranibizumab at a dose of 0.5 mg. Best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were recorded at baseline and during follow-up. RNFL thickness and optic disc parameters were assessed using optical coherence tomography (OCT) and Heidelberg Retina Tomograph III (HRT-3). Measurements were obtained before treatment and at 1 week, 1 month, 3 months, and 6 months after injection. Comparisons were performed within and between disease groups. Results: Of the 60 patients, 31 (51.7%) had DME, 20 (33.3%) had AMD, and 9 (15.0%) had RVO. Best-corrected visual acuity improved significantly during the follow-up period. Mean RNFL thickness measured by OCT showed a significant reduction in the DME and RVO groups (p = 0.0001 and p = 0.043, respectively). In contrast, no significant changes in RNFL thickness were detected using HRT-3, and no consistent alterations in other optic disc parameters were observed. Changes in optic disc parameters varied among disease groups. Conclusions: Intravitreal ranibizumab treatment was associated with a reduction in mean RNFL thickness measured by OCT in patients with DME and RVO during a six-month follow-up period, whereas no corresponding RNFL thinning was detected using HRT-3 in any disease group. The observed optic disc parameter changes appeared to be disease specific. Given the absence of untreated control eyes and the exclusion of patients with glaucoma, these findings apply only to non-glaucomatous eyes and should not be extrapolated to patients with glaucoma. Further prospective studies with larger cohorts, appropriate control groups, and longer follow-up durations are warranted to clarify the long-term effects of anti-VEGF therapy on the optic nerve.<\/jats:p>","DOI":"10.3390\/jcm15020449","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:26:56Z","timestamp":1767774416000},"page":"449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Effect of Intravitreal Ranibizumab Injection on Retinal Nerve Fiber Layer Thickness and Optic Disc Parameters"],"prefix":"10.3390","volume":"15","author":[{"given":"G\u00fclin Tu\u011fba","family":"Ongun","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Antalya City Hospital, Antalya 07230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Ya\u011fc\u0131","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Isparta Private Hospital, Isparta 32040, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/ICU.0b013e3282f0ca54","article-title":"Anti-vascular endothelial growth factor therapy for ocular neovascular disease","volume":"18","author":"Andreoli","year":"2007","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kanski, J. (2011). Acquired Macular Disorders: Clinical Ophthalmology. A Systematic Approach, Elsevier. [7th ed.].","DOI":"10.1016\/B978-0-7020-4093-1.00014-8"},{"key":"ref_4","first-page":"233","article-title":"Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18","volume":"39","author":"Davis","year":"1998","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Diabetic Retinopathy Clinical Research Network, Elman, M.J., Aiello, L.P., Beck, R.W., Bressler, N.M., Bressler, S.B., Edwards, A.R., Ferris, F.L., Friedman, S.M., and Glassman, A.R. (2010). Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology, 117, 1064\u20131077.e35.","DOI":"10.1016\/j.ophtha.2010.02.031"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Seddon, J.M., and Sobrin, L. (2013). Epidemiology and risk factors for age-related macular degeneration. Retina, Elsevier. [5th ed.].","DOI":"10.1016\/B978-1-4557-0737-9.00063-1"},{"key":"ref_7","unstructured":"Yanoff, M., and Duker, J.S. (2014). Macular Dystrophies. Ophthalmology, Elsevier. [4th ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0161-6420(98)93020-2","article-title":"Vascular endothelial growth factor upregulation in human central retinal vein occlusion","volume":"105","author":"Folberg","year":"1998","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0002-9394(14)70221-1","article-title":"Scanning laser polarimetry to measure the nerve fiber layer of normal and glaucomatous eyes","volume":"119","author":"Weinreb","year":"1995","journal-title":"Am. J. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/bjo.86.7.725","article-title":"Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy","volume":"86","author":"Russ","year":"2002","journal-title":"Br. J. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1364\/OPEX.12.002404","article-title":"Ultrahigh resolution, high-speed, Fourier domain optical coherence tomography and methods for dispersion compensation","volume":"12","author":"Wojtkowski","year":"2004","journal-title":"Opt. Express"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/archopht.123.12.1715","article-title":"Spectral domain optical coherence tomography: Ultra-high speed, ultra-high resolution ophthalmic imaging","volume":"123","author":"Chen","year":"2005","journal-title":"Arch. Ophthalmol."},{"key":"ref_14","unstructured":"Carl Zeiss Meditec (2025, December 27). Stratus OCT 3000. Available online: https:\/\/www.meditec.zeiss.com."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1167\/iovs.03-0514","article-title":"Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using StratusOCT","volume":"45","author":"Paunescu","year":"2004","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_16","first-page":"498","article-title":"Optical coherence tomography disc assessment in optic nerves with peripapillary atrophy","volume":"34","author":"Lai","year":"2003","journal-title":"Ophthalmic Surg. Lasers Imaging"},{"key":"ref_17","unstructured":"(2025, December 27). Heidelberg Retinal Tomograph Glaucoma Module. Heidelberg Engineering. Available online: http:\/\/www.heidelbergengineering.com."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3129\/i07-172","article-title":"Short-term intraocular pressure changes after intravitreal injection of bevacizumab","volume":"42","author":"Hollands","year":"2007","journal-title":"Can. J. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3928\/15428877-20090430-12","article-title":"Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections","volume":"40","author":"Kahook","year":"2009","journal-title":"Ophthalmic Surg. Lasers Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2011.01.053","article-title":"Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration","volume":"152","author":"Day","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.ophtha.2004.12.041","article-title":"Comparison of arteritis and nonarteritic anterior ischemic optic neuropathies with the Heidelberg Retina Tomograph","volume":"112","author":"Savino","year":"2005","journal-title":"Ophthalmology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1523\/JNEUROSCI.19-14-05731.1999","article-title":"Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system","volume":"19","author":"Sondell","year":"1999","journal-title":"J. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/bies.20092","article-title":"VEGF: Once regarded as a specific angiogenic factor, now implicated in neuroprotection","volume":"26","author":"Storkebaum","year":"2004","journal-title":"BioEssays"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1167\/iovs.13-13769","article-title":"Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor","volume":"55","author":"Shin","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/IAE.0b013e3181a91dfd","article-title":"Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents","volume":"29","author":"Seth","year":"2009","journal-title":"Retina"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1038\/s41598-021-84648-1","article-title":"Effect of intravitreal ranibizumab and aflibercept injections on retinal nerve fiber layer thickness","volume":"11","author":"Ahn","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6214","DOI":"10.1167\/iovs.12-9875","article-title":"Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab","volume":"53","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_29","first-page":"1269","article-title":"Evaluation of the effect of intravitreal ranibizumab injections in patients with neovascular age-related macular degeneration on retinal nerve fiber layer thickness using optical coherence tomography","volume":"9","author":"Lascaratos","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10792-014-9972-2","article-title":"The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration","volume":"35","author":"Parlak","year":"2015","journal-title":"Int. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1167\/iovs.15-18404","article-title":"Intravitreal Anti-Vascular Endothelial Growth Factor Therapy and Retinal Nerve Fiber Layer Loss in Eyes with Age Related Macular Degeneration: A Meta-Analysis","volume":"57","author":"Shin","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajo.2006.02.016","article-title":"Diabetes-associated retinal nerve fiber damage evaluated with scanning laser polarimetry","volume":"142","author":"Takahashi","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF00183592","article-title":"Optic disc morphology in diabetes mellitus","volume":"233","author":"Jonas","year":"1995","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1167\/iovs.07-0655","article-title":"Impact of diabetic retinopathy on quantitative retinal nerve fiber layer measurement and glaucoma screening","volume":"49","author":"Takahashi","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/IJG.0b013e318193c29f","article-title":"Comparison of retinal nerve fiber layer thickness values using Stratus Optical Coherence Tomography and Heidelberg Retina Tomograph-III","volume":"18","author":"Olmo","year":"2009","journal-title":"J. Glaucoma"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:40:54Z","timestamp":1767775254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15020449"],"URL":"https:\/\/doi.org\/10.3390\/jcm15020449","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]}}}